Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR2554 with CHOP/CHOEP in Peripheral T-cell Lymphoma
NCT06173999Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zeprumetostat in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by Hengrui. Primary endpoints: incidence and severity of adverse events (AEs) at 6 months and Overall response rate at 90 days. Started Dec 2023; status: recruiting.
02
Drugs
zeprumetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06173999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06173999.